This company listing is no longer active
Clover Biopharmaceuticals Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.
Key information
n/a
Earnings growth rate
190.4%
EPS growth rate
| Biotechs earnings growth | 40.0% |
| Revenue growth rate | 47.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Jul 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 2,341 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 3,071 | N/A | N/A | N/A | 2 |
| 12/31/2023 | 2,571 | N/A | N/A | N/A | 2 |
| 6/30/2023 | 0 | -665 | N/A | N/A | N/A |
| 3/31/2023 | 0 | -1,559 | N/A | N/A | N/A |
| 12/31/2022 | N/A | -2,452 | -1,796 | -1,691 | N/A |
| 9/30/2022 | N/A | -4,145 | -1,461 | -1,356 | N/A |
| 6/30/2022 | N/A | -5,838 | -1,125 | -1,021 | N/A |
| 3/31/2022 | N/A | -5,927 | -1,062 | -969 | N/A |
| 12/31/2021 | N/A | -6,016 | -998 | -918 | N/A |
| 12/31/2020 | N/A | -913 | 363 | 477 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).
High Growth Revenue: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time